Clinical Trial Update: Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial is evaluating the combination of ruxolitinib and enzalutamide for metastatic castration-resistant prostate cancer; the study is curre…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Enzalutamide (enzalutamide)
• Ruxolitinib (ruxolitinib)

Snippet

Sponsor: University of Michigan Rogel Cancer Center | Conditions: Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma | Phase 1, Phase 2 | Status: RECRUITING